Kevin Lillehei
Concepts (614)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pituitary Neoplasms | 29 | 2025 | 192 | 3.610 |
Why?
| | Adenoma | 23 | 2025 | 219 | 3.190 |
Why?
| | Brain Neoplasms | 48 | 2023 | 1267 | 2.990 |
Why?
| | Neurosurgical Procedures | 11 | 2025 | 204 | 2.040 |
Why?
| | Meningioma | 12 | 2022 | 94 | 1.950 |
Why?
| | Pituitary Gland | 11 | 2020 | 150 | 1.720 |
Why?
| | Central Nervous System Cysts | 3 | 2020 | 13 | 1.610 |
Why?
| | Glioblastoma | 18 | 2023 | 341 | 1.590 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2022 | 1057 | 1.380 |
Why?
| | Meningeal Neoplasms | 6 | 2022 | 101 | 1.290 |
Why?
| | Peripheral Nervous System Neoplasms | 6 | 2009 | 19 | 1.100 |
Why?
| | Central Nervous System Neoplasms | 7 | 2017 | 165 | 0.930 |
Why?
| | Glioma | 15 | 2020 | 407 | 0.900 |
Why?
| | Radiotherapy, Intensity-Modulated | 5 | 2016 | 137 | 0.860 |
Why?
| | Sphenoid Bone | 2 | 2016 | 17 | 0.850 |
Why?
| | Gliosarcoma | 5 | 2006 | 8 | 0.840 |
Why?
| | Cysts | 3 | 2020 | 114 | 0.760 |
Why?
| | Carmustine | 3 | 2017 | 53 | 0.720 |
Why?
| | Pituitary ACTH Hypersecretion | 2 | 2018 | 11 | 0.700 |
Why?
| | Evidence-Based Medicine | 1 | 2025 | 745 | 0.690 |
Why?
| | Cancer Vaccines | 5 | 2018 | 166 | 0.690 |
Why?
| | Neoplasms, Radiation-Induced | 4 | 2008 | 91 | 0.680 |
Why?
| | Hypopituitarism | 1 | 2020 | 16 | 0.650 |
Why?
| | Rhabdoid Tumor | 3 | 2010 | 98 | 0.640 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2019 | 122 | 0.600 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2016 | 215 | 0.590 |
Why?
| | Polyesters | 2 | 2017 | 77 | 0.560 |
Why?
| | Decanoic Acids | 1 | 2017 | 8 | 0.560 |
Why?
| | Bleomycin | 1 | 2019 | 247 | 0.560 |
Why?
| | Immunotherapy | 4 | 2006 | 634 | 0.550 |
Why?
| | Magnetic Resonance Imaging | 29 | 2022 | 3637 | 0.540 |
Why?
| | Adult | 72 | 2025 | 38201 | 0.530 |
Why?
| | Middle Aged | 73 | 2025 | 33604 | 0.520 |
Why?
| | Orbital Diseases | 1 | 2016 | 34 | 0.510 |
Why?
| | Aged | 54 | 2025 | 24024 | 0.480 |
Why?
| | Humans | 126 | 2025 | 138651 | 0.450 |
Why?
| | Male | 86 | 2025 | 68260 | 0.440 |
Why?
| | Female | 83 | 2025 | 73763 | 0.400 |
Why?
| | Brachial Plexus | 3 | 2007 | 33 | 0.390 |
Why?
| | Antineoplastic Agents | 5 | 2017 | 2152 | 0.390 |
Why?
| | Retrospective Studies | 28 | 2025 | 15909 | 0.380 |
Why?
| | Biomarkers, Tumor | 8 | 2017 | 1224 | 0.380 |
Why?
| | Dacarbazine | 7 | 2015 | 98 | 0.370 |
Why?
| | Skull Neoplasms | 4 | 2012 | 21 | 0.360 |
Why?
| | Chemoradiotherapy | 4 | 2015 | 230 | 0.360 |
Why?
| | Craniopharyngioma | 3 | 2020 | 73 | 0.350 |
Why?
| | Cisplatin | 3 | 1998 | 327 | 0.350 |
Why?
| | Extracellular Vesicles | 2 | 2024 | 148 | 0.340 |
Why?
| | Immunotherapy, Adoptive | 5 | 1997 | 349 | 0.340 |
Why?
| | Cautery | 1 | 2010 | 4 | 0.340 |
Why?
| | Antineoplastic Agents, Alkylating | 5 | 2013 | 70 | 0.330 |
Why?
| | Epithelioid Cells | 1 | 2010 | 8 | 0.330 |
Why?
| | Sella Turcica | 5 | 2018 | 17 | 0.330 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 2 | 2024 | 11 | 0.320 |
Why?
| | Monosomy | 1 | 2010 | 12 | 0.320 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2010 | 45 | 0.320 |
Why?
| | Astrocytoma | 5 | 2014 | 128 | 0.320 |
Why?
| | Neurosurgery | 2 | 2021 | 41 | 0.320 |
Why?
| | Combined Modality Therapy | 11 | 2016 | 1235 | 0.320 |
Why?
| | Hemangioma | 1 | 2009 | 43 | 0.310 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2010 | 124 | 0.300 |
Why?
| | Cadherins | 2 | 2024 | 201 | 0.300 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2010 | 310 | 0.300 |
Why?
| | Membrane Proteins | 2 | 2017 | 1145 | 0.290 |
Why?
| | Sarcoma, Ewing | 1 | 2009 | 98 | 0.280 |
Why?
| | Young Adult | 16 | 2025 | 13305 | 0.280 |
Why?
| | Spinal Nerve Roots | 2 | 2006 | 29 | 0.270 |
Why?
| | DNA Mutational Analysis | 3 | 2014 | 398 | 0.270 |
Why?
| | Fibromatosis, Abdominal | 1 | 2007 | 3 | 0.270 |
Why?
| | Tumor Cells, Cultured | 8 | 2017 | 956 | 0.270 |
Why?
| | Immunohistochemistry | 13 | 2011 | 1731 | 0.260 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2024 | 1388 | 0.260 |
Why?
| | Prolactinoma | 3 | 2019 | 14 | 0.260 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2006 | 36 | 0.250 |
Why?
| | Diagnosis, Differential | 8 | 2010 | 1482 | 0.250 |
Why?
| | Brachial Plexus Neuropathies | 1 | 2006 | 19 | 0.250 |
Why?
| | Oligonucleotides, Antisense | 1 | 2006 | 110 | 0.240 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 2 | 2017 | 12 | 0.240 |
Why?
| | Gonadotrophs | 5 | 2015 | 22 | 0.240 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 67 | 0.240 |
Why?
| | Ethanol | 1 | 2010 | 614 | 0.240 |
Why?
| | Rats, Inbred F344 | 7 | 2006 | 267 | 0.230 |
Why?
| | Oligonucleotide Array Sequence Analysis | 7 | 2015 | 761 | 0.220 |
Why?
| | Chordoma | 1 | 2024 | 14 | 0.220 |
Why?
| | Interleukin-2 | 6 | 1997 | 451 | 0.220 |
Why?
| | Neoplasms | 5 | 2013 | 2681 | 0.220 |
Why?
| | Treatment Outcome | 12 | 2020 | 10923 | 0.220 |
Why?
| | Hemangioblastoma | 1 | 2004 | 2 | 0.220 |
Why?
| | DNA-Binding Proteins | 2 | 2010 | 1471 | 0.210 |
Why?
| | Adolescent | 20 | 2020 | 21564 | 0.210 |
Why?
| | Neoplasms, Second Primary | 4 | 2012 | 109 | 0.210 |
Why?
| | Postoperative Complications | 8 | 2018 | 2722 | 0.210 |
Why?
| | Osteoblasts | 1 | 2024 | 131 | 0.210 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2004 | 148 | 0.210 |
Why?
| | Cell Movement | 2 | 2024 | 969 | 0.210 |
Why?
| | Neurologic Examination | 3 | 2019 | 128 | 0.200 |
Why?
| | Cauda Equina | 2 | 2004 | 6 | 0.200 |
Why?
| | Transcription Factors | 2 | 2010 | 1697 | 0.200 |
Why?
| | Inappropriate ADH Syndrome | 2 | 2018 | 8 | 0.200 |
Why?
| | Drug Implants | 3 | 2017 | 83 | 0.200 |
Why?
| | Postoperative Period | 3 | 2020 | 355 | 0.200 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 210 | 0.190 |
Why?
| | Neuroendocrine Tumors | 1 | 2024 | 109 | 0.190 |
Why?
| | Motor Cortex | 1 | 2003 | 61 | 0.190 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2000 | 174 | 0.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2015 | 1742 | 0.190 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2012 | 525 | 0.190 |
Why?
| | Pituitary Diseases | 3 | 2017 | 20 | 0.190 |
Why?
| | Pineal Gland | 1 | 2021 | 16 | 0.180 |
Why?
| | Pinealoma | 1 | 2021 | 10 | 0.180 |
Why?
| | Prognosis | 10 | 2021 | 3984 | 0.180 |
Why?
| | Fistula | 1 | 2022 | 47 | 0.180 |
Why?
| | Aspergillus | 2 | 2013 | 19 | 0.180 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2014 | 222 | 0.180 |
Why?
| | Frontal Bone | 2 | 2015 | 21 | 0.180 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2016 | 57 | 0.180 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 857 | 0.180 |
Why?
| | Follow-Up Studies | 8 | 2017 | 5112 | 0.170 |
Why?
| | Ki-67 Antigen | 4 | 2011 | 111 | 0.170 |
Why?
| | Neuropathology | 1 | 2020 | 4 | 0.170 |
Why?
| | Telepathology | 1 | 2020 | 4 | 0.170 |
Why?
| | Intracranial Hypotension | 1 | 2022 | 56 | 0.170 |
Why?
| | Prospective Studies | 11 | 2023 | 7554 | 0.170 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 669 | 0.170 |
Why?
| | Paraneoplastic Endocrine Syndromes | 1 | 2000 | 1 | 0.160 |
Why?
| | Esthesioneuroblastoma, Olfactory | 1 | 2000 | 2 | 0.160 |
Why?
| | Reactive Oxygen Species | 2 | 2000 | 624 | 0.160 |
Why?
| | Fluorescein | 1 | 2020 | 24 | 0.160 |
Why?
| | Salivary Glands | 1 | 2020 | 34 | 0.160 |
Why?
| | Stereotaxic Techniques | 1 | 2020 | 40 | 0.160 |
Why?
| | Survival Analysis | 7 | 2018 | 1309 | 0.160 |
Why?
| | Nose Neoplasms | 1 | 2000 | 24 | 0.160 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2000 | 26 | 0.160 |
Why?
| | Transcriptome | 3 | 2024 | 967 | 0.160 |
Why?
| | Radiosurgery | 3 | 2010 | 389 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 12 | 2022 | 2698 | 0.160 |
Why?
| | Genes, Tumor Suppressor | 2 | 2017 | 80 | 0.150 |
Why?
| | Lung Neoplasms | 3 | 2013 | 2527 | 0.150 |
Why?
| | Neoplasm Grading | 2 | 2017 | 305 | 0.150 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 5 | 0.150 |
Why?
| | Dendritic Cells | 2 | 2023 | 491 | 0.150 |
Why?
| | Hemangioma, Cavernous | 1 | 1998 | 14 | 0.150 |
Why?
| | Polyethylenes | 1 | 2018 | 15 | 0.150 |
Why?
| | Oligodendroglioma | 2 | 2014 | 13 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2015 | 375 | 0.150 |
Why?
| | Aged, 80 and over | 12 | 2020 | 7677 | 0.150 |
Why?
| | Endocrine Glands | 1 | 1998 | 16 | 0.150 |
Why?
| | International Educational Exchange | 1 | 2018 | 12 | 0.150 |
Why?
| | ErbB Receptors | 4 | 2006 | 609 | 0.150 |
Why?
| | Stroke | 2 | 2021 | 1136 | 0.150 |
Why?
| | Sphenoid Sinus | 1 | 2018 | 11 | 0.140 |
Why?
| | Survival Rate | 6 | 2015 | 1935 | 0.140 |
Why?
| | Antioxidants | 2 | 2000 | 593 | 0.140 |
Why?
| | Time Factors | 10 | 2011 | 6851 | 0.140 |
Why?
| | Hyponatremia | 1 | 2018 | 43 | 0.140 |
Why?
| | Adenocarcinoma | 2 | 2004 | 885 | 0.140 |
Why?
| | Remission Induction | 1 | 2018 | 293 | 0.140 |
Why?
| | Cerebrovascular Disorders | 1 | 1998 | 96 | 0.140 |
Why?
| | Quinazolines | 2 | 2010 | 249 | 0.140 |
Why?
| | Mutation | 3 | 2014 | 3987 | 0.140 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2017 | 28 | 0.140 |
Why?
| | Prostheses and Implants | 1 | 2018 | 143 | 0.130 |
Why?
| | Rats | 8 | 2006 | 5594 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1746 | 0.130 |
Why?
| | Thalamic Diseases | 1 | 2017 | 4 | 0.130 |
Why?
| | Xanthomatosis | 1 | 2017 | 8 | 0.130 |
Why?
| | Desmosomes | 1 | 2017 | 21 | 0.130 |
Why?
| | Third Ventricle | 1 | 2017 | 16 | 0.130 |
Why?
| | Reoperation | 5 | 2020 | 579 | 0.130 |
Why?
| | Exophthalmos | 1 | 2016 | 19 | 0.130 |
Why?
| | Students, Medical | 1 | 2021 | 355 | 0.130 |
Why?
| | Cell Proliferation | 5 | 2015 | 2480 | 0.120 |
Why?
| | Cytokines | 2 | 2021 | 2080 | 0.120 |
Why?
| | Brain Injuries | 1 | 2021 | 501 | 0.120 |
Why?
| | Progesterone | 1 | 2017 | 258 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1111 | 0.120 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 24 | 0.120 |
Why?
| | Neurothekeoma | 1 | 1995 | 4 | 0.120 |
Why?
| | Tibial Nerve | 1 | 1995 | 9 | 0.120 |
Why?
| | Occipital Lobe | 2 | 2006 | 23 | 0.120 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 74 | 0.120 |
Why?
| | Glycoproteins | 3 | 2012 | 354 | 0.120 |
Why?
| | Genes, p53 | 2 | 2011 | 67 | 0.120 |
Why?
| | Olfactory Pathways | 1 | 2015 | 38 | 0.110 |
Why?
| | Proteome | 2 | 2024 | 469 | 0.110 |
Why?
| | Accidents, Aviation | 1 | 1994 | 6 | 0.110 |
Why?
| | Antigens, Neoplasm | 2 | 2013 | 316 | 0.110 |
Why?
| | Karyotyping | 3 | 2008 | 103 | 0.110 |
Why?
| | Molecular Chaperones | 2 | 2013 | 196 | 0.110 |
Why?
| | Orbit | 1 | 2015 | 71 | 0.110 |
Why?
| | Biocompatible Materials | 1 | 2018 | 425 | 0.110 |
Why?
| | Neoplasm Invasiveness | 6 | 2014 | 501 | 0.110 |
Why?
| | Acromegaly | 1 | 2014 | 16 | 0.110 |
Why?
| | Cranial Irradiation | 1 | 1995 | 85 | 0.110 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 39 | 0.110 |
Why?
| | Intervertebral Disc Displacement | 2 | 1998 | 41 | 0.110 |
Why?
| | Ganglioglioma | 1 | 2014 | 35 | 0.110 |
Why?
| | Human Growth Hormone | 1 | 2014 | 48 | 0.110 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 26 | 0.110 |
Why?
| | Pituitary Gland, Posterior | 1 | 2013 | 2 | 0.100 |
Why?
| | Ganglioneuroma | 1 | 2013 | 2 | 0.100 |
Why?
| | Cerebral Hemorrhage | 2 | 1985 | 114 | 0.100 |
Why?
| | Seizures | 1 | 2017 | 431 | 0.100 |
Why?
| | Sarcoma, Alveolar Soft Part | 1 | 1993 | 6 | 0.100 |
Why?
| | Immune Tolerance | 2 | 2008 | 366 | 0.100 |
Why?
| | Aspergillosis | 1 | 2013 | 22 | 0.100 |
Why?
| | Child | 9 | 2022 | 21921 | 0.100 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 19 | 0.100 |
Why?
| | Telomerase | 3 | 2003 | 246 | 0.100 |
Why?
| | Joint Dislocations | 1 | 1993 | 51 | 0.100 |
Why?
| | Cell Division | 5 | 2012 | 794 | 0.100 |
Why?
| | Spinal Injuries | 1 | 1993 | 56 | 0.100 |
Why?
| | Neoplasm Transplantation | 3 | 2000 | 250 | 0.100 |
Why?
| | Patient Readmission | 1 | 2018 | 703 | 0.100 |
Why?
| | Dog Diseases | 1 | 2013 | 65 | 0.100 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2009 | 83 | 0.090 |
Why?
| | Muscles | 1 | 1993 | 332 | 0.090 |
Why?
| | Soft Tissue Neoplasms | 1 | 1993 | 116 | 0.090 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1047 | 0.090 |
Why?
| | Craniotomy | 3 | 2015 | 79 | 0.090 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2012 | 58 | 0.090 |
Why?
| | Drug Resistance, Multiple | 2 | 2001 | 25 | 0.090 |
Why?
| | Spine | 1 | 1993 | 179 | 0.090 |
Why?
| | Curriculum | 1 | 2018 | 1009 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 82 | 0.090 |
Why?
| | Skull | 2 | 2007 | 150 | 0.090 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3392 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 1118 | 0.090 |
Why?
| | Mitotic Index | 2 | 2011 | 24 | 0.090 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2010 | 8 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2851 | 0.090 |
Why?
| | Hyperthermia, Induced | 2 | 2002 | 120 | 0.080 |
Why?
| | Adenoma, Oxyphilic | 1 | 2010 | 7 | 0.080 |
Why?
| | Claudins | 1 | 2010 | 24 | 0.080 |
Why?
| | Tumor Burden | 4 | 2012 | 309 | 0.080 |
Why?
| | SMARCB1 Protein | 1 | 2010 | 29 | 0.080 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 11 | 0.080 |
Why?
| | Tanzania | 2 | 2020 | 56 | 0.080 |
Why?
| | Animals | 14 | 2013 | 37217 | 0.080 |
Why?
| | Immunity, Cellular | 2 | 2003 | 269 | 0.080 |
Why?
| | Lymphoma | 2 | 2008 | 227 | 0.080 |
Why?
| | Registries | 1 | 2017 | 2073 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 320 | 0.070 |
Why?
| | Neuroaspergillosis | 1 | 2008 | 2 | 0.070 |
Why?
| | Piperidines | 1 | 2010 | 216 | 0.070 |
Why?
| | Brain Abscess | 1 | 2008 | 10 | 0.070 |
Why?
| | Killer Cells, Lymphokine-Activated | 4 | 1993 | 12 | 0.070 |
Why?
| | Cytogenetics | 1 | 2008 | 10 | 0.070 |
Why?
| | Cell Survival | 5 | 2015 | 1123 | 0.070 |
Why?
| | Genetic Vectors | 2 | 2008 | 336 | 0.070 |
Why?
| | Arm Injuries | 1 | 1988 | 23 | 0.070 |
Why?
| | Prolactin | 3 | 2019 | 96 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 616 | 0.070 |
Why?
| | Dogs | 2 | 2013 | 426 | 0.070 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2006 | 224 | 0.070 |
Why?
| | Internship and Residency | 1 | 2018 | 1187 | 0.070 |
Why?
| | Transcription Factor Pit-1 | 2 | 2025 | 27 | 0.070 |
Why?
| | Steroidogenic Factor 1 | 2 | 2025 | 12 | 0.070 |
Why?
| | Drug Administration Schedule | 3 | 2010 | 768 | 0.070 |
Why?
| | Radiotherapy Dosage | 3 | 2010 | 281 | 0.070 |
Why?
| | Interferon-beta | 1 | 2008 | 92 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 1988 | 71 | 0.070 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2008 | 98 | 0.070 |
Why?
| | Mesenchymoma | 1 | 2007 | 9 | 0.070 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2007 | 17 | 0.070 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2007 | 12 | 0.070 |
Why?
| | Hematoma | 2 | 1985 | 54 | 0.070 |
Why?
| | Superoxide Dismutase | 2 | 2000 | 352 | 0.070 |
Why?
| | Scalp | 1 | 2007 | 35 | 0.070 |
Why?
| | Adenoviridae | 1 | 2008 | 200 | 0.070 |
Why?
| | Wounds and Injuries | 1 | 1994 | 833 | 0.060 |
Why?
| | Radiography | 3 | 2013 | 841 | 0.060 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 42 | 0.060 |
Why?
| | Blood Vessels | 1 | 1988 | 180 | 0.060 |
Why?
| | Neoplasm Staging | 4 | 2015 | 1372 | 0.060 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 460 | 0.060 |
Why?
| | Enophthalmos | 1 | 2006 | 2 | 0.060 |
Why?
| | Base Pair Mismatch | 1 | 2006 | 10 | 0.060 |
Why?
| | Hemangioma, Capillary | 1 | 2006 | 13 | 0.060 |
Why?
| | Dexamethasone | 4 | 2012 | 375 | 0.060 |
Why?
| | Blepharoptosis | 1 | 2006 | 12 | 0.060 |
Why?
| | Child, Preschool | 5 | 2017 | 11158 | 0.060 |
Why?
| | Epidermal Cyst | 1 | 2006 | 13 | 0.060 |
Why?
| | Immunoprecipitation | 1 | 2006 | 154 | 0.060 |
Why?
| | Injections, Subcutaneous | 1 | 2006 | 162 | 0.060 |
Why?
| | Imatinib Mesylate | 1 | 2006 | 80 | 0.060 |
Why?
| | Parietal Lobe | 1 | 2006 | 60 | 0.060 |
Why?
| | Lymphoma, Follicular | 1 | 2006 | 53 | 0.060 |
Why?
| | Brain Edema | 2 | 2004 | 64 | 0.060 |
Why?
| | Teratoma | 1 | 2007 | 118 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 462 | 0.060 |
Why?
| | Karnofsky Performance Status | 3 | 2013 | 36 | 0.060 |
Why?
| | Vaccination | 2 | 2023 | 1437 | 0.060 |
Why?
| | Chest Pain | 1 | 2006 | 96 | 0.060 |
Why?
| | Neoplasm, Residual | 2 | 2020 | 130 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2008 | 314 | 0.060 |
Why?
| | Bone Diseases | 1 | 2006 | 64 | 0.060 |
Why?
| | Ultrasonics | 2 | 2002 | 50 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2010 | 204 | 0.060 |
Why?
| | Benzamides | 1 | 2006 | 213 | 0.060 |
Why?
| | Wounds, Nonpenetrating | 1 | 1988 | 304 | 0.060 |
Why?
| | Lymphoma, B-Cell | 1 | 2006 | 127 | 0.060 |
Why?
| | Exons | 1 | 2006 | 353 | 0.060 |
Why?
| | Cushing Syndrome | 1 | 2004 | 9 | 0.060 |
Why?
| | Medulloblastoma | 1 | 2007 | 202 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2006 | 4315 | 0.060 |
Why?
| | Calcitonin | 1 | 2004 | 29 | 0.050 |
Why?
| | Databases, Factual | 1 | 2010 | 1415 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2030 | 0.050 |
Why?
| | Myelography | 2 | 2022 | 37 | 0.050 |
Why?
| | Subarachnoid Space | 1 | 2004 | 9 | 0.050 |
Why?
| | Bevacizumab | 2 | 2015 | 139 | 0.050 |
Why?
| | S100 Proteins | 2 | 1995 | 37 | 0.050 |
Why?
| | von Hippel-Lindau Disease | 1 | 2004 | 12 | 0.050 |
Why?
| | United States | 3 | 2017 | 14938 | 0.050 |
Why?
| | Brain | 6 | 2017 | 2792 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 984 | 0.050 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 18 | 0.050 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2003 | 15 | 0.050 |
Why?
| | Radiotherapy | 1 | 2004 | 207 | 0.050 |
Why?
| | Piperazines | 1 | 2006 | 345 | 0.050 |
Why?
| | Craniocerebral Trauma | 1 | 1985 | 170 | 0.050 |
Why?
| | Proteomics | 2 | 2024 | 1110 | 0.050 |
Why?
| | Lymphocyte Activation | 3 | 1993 | 1148 | 0.050 |
Why?
| | Polymers | 2 | 1997 | 487 | 0.050 |
Why?
| | Quality of Life | 2 | 2013 | 2954 | 0.050 |
Why?
| | Age Factors | 4 | 2014 | 3256 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 600 | 0.050 |
Why?
| | Image Enhancement | 1 | 2004 | 191 | 0.050 |
Why?
| | Dura Mater | 2 | 2000 | 34 | 0.050 |
Why?
| | Incidence | 3 | 2003 | 2747 | 0.050 |
Why?
| | Pyrimidines | 1 | 2006 | 472 | 0.050 |
Why?
| | Disease Progression | 2 | 2021 | 2749 | 0.050 |
Why?
| | Neoplasm Proteins | 2 | 2003 | 429 | 0.050 |
Why?
| | Transferases | 1 | 2022 | 31 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2004 | 314 | 0.050 |
Why?
| | Microtubule-Associated Proteins | 1 | 2003 | 195 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2024 | 488 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3523 | 0.050 |
Why?
| | DNA, Neoplasm | 3 | 2005 | 157 | 0.040 |
Why?
| | Thyrotropin | 5 | 1999 | 117 | 0.040 |
Why?
| | Spinal Cord | 1 | 2004 | 373 | 0.040 |
Why?
| | Public Opinion | 1 | 2021 | 67 | 0.040 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2022 | 62 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2003 | 801 | 0.040 |
Why?
| | Neuroimmunomodulation | 1 | 2000 | 66 | 0.040 |
Why?
| | Gene Amplification | 2 | 2015 | 102 | 0.040 |
Why?
| | Ethmoid Sinus | 1 | 2000 | 9 | 0.040 |
Why?
| | Frontal Sinus | 1 | 2000 | 6 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2021 | 168 | 0.040 |
Why?
| | Arginine Vasopressin | 1 | 2000 | 43 | 0.040 |
Why?
| | Immunosuppressive Agents | 2 | 2008 | 849 | 0.040 |
Why?
| | Free Radicals | 1 | 2000 | 114 | 0.040 |
Why?
| | Visual Fields | 1 | 2020 | 115 | 0.040 |
Why?
| | Pituitary Hormones | 1 | 1999 | 16 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2003 | 313 | 0.040 |
Why?
| | Dopamine Agonists | 1 | 2019 | 43 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2007 | 837 | 0.040 |
Why?
| | Gonadotropins, Pituitary | 2 | 2008 | 22 | 0.040 |
Why?
| | Chromosomes, Human, Pair 7 | 2 | 2005 | 17 | 0.040 |
Why?
| | Cerebral Cortex | 2 | 1998 | 452 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 1084 | 0.040 |
Why?
| | Depressive Disorder, Major | 1 | 2003 | 374 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 359 | 0.040 |
Why?
| | Up-Regulation | 2 | 2015 | 851 | 0.040 |
Why?
| | Infant | 2 | 2008 | 9574 | 0.040 |
Why?
| | Hot Temperature | 1 | 2001 | 393 | 0.040 |
Why?
| | Apoptosis | 2 | 2015 | 2546 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 1998 | 35 | 0.040 |
Why?
| | Cerebral Veins | 1 | 1998 | 16 | 0.040 |
Why?
| | Biopsy | 2 | 2017 | 1072 | 0.040 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 6 | 0.040 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 22 | 0.040 |
Why?
| | Catheters, Indwelling | 1 | 1998 | 90 | 0.040 |
Why?
| | Capacity Building | 1 | 2018 | 62 | 0.040 |
Why?
| | Leiomyosarcoma | 1 | 1998 | 28 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 168 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2018 | 77 | 0.030 |
Why?
| | Meningomyelocele | 1 | 1998 | 59 | 0.030 |
Why?
| | Visual Acuity | 1 | 2020 | 428 | 0.030 |
Why?
| | Drug Synergism | 1 | 1998 | 368 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2000 | 333 | 0.030 |
Why?
| | Preoperative Care | 2 | 2003 | 367 | 0.030 |
Why?
| | Leiomyoma | 1 | 1998 | 55 | 0.030 |
Why?
| | Brain Diseases | 2 | 1998 | 148 | 0.030 |
Why?
| | Cell Line | 3 | 2012 | 2876 | 0.030 |
Why?
| | Hypophysitis | 1 | 2017 | 3 | 0.030 |
Why?
| | Neuroectodermal Tumors, Primitive | 1 | 1997 | 11 | 0.030 |
Why?
| | Ventriculostomy | 1 | 2017 | 21 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2000 | 786 | 0.030 |
Why?
| | Hydrocephalus | 2 | 2017 | 108 | 0.030 |
Why?
| | Neuroendoscopy | 1 | 2017 | 23 | 0.030 |
Why?
| | Premenopause | 1 | 2017 | 122 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2017 | 116 | 0.030 |
Why?
| | Gonadotropins | 2 | 1999 | 40 | 0.030 |
Why?
| | DNA Methylation | 1 | 2022 | 629 | 0.030 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 209 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 1996 | 114 | 0.030 |
Why?
| | Granuloma | 1 | 2017 | 97 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2017 | 91 | 0.030 |
Why?
| | Biodegradation, Environmental | 1 | 1996 | 87 | 0.030 |
Why?
| | RNA, Messenger | 5 | 2011 | 2815 | 0.030 |
Why?
| | Postoperative Care | 1 | 1998 | 274 | 0.030 |
Why?
| | Cognition Disorders | 2 | 2015 | 511 | 0.030 |
Why?
| | Developing Countries | 1 | 2018 | 311 | 0.030 |
Why?
| | Immunophenotyping | 1 | 1997 | 327 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 1997 | 175 | 0.030 |
Why?
| | Drainage | 1 | 2017 | 173 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 148 | 0.030 |
Why?
| | Endoscopy | 1 | 2018 | 320 | 0.030 |
Why?
| | Hyperostosis | 1 | 1995 | 5 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 935 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2005 | 1323 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 320 | 0.030 |
Why?
| | Signal Transduction | 3 | 2015 | 5086 | 0.030 |
Why?
| | Olfactory Nerve | 1 | 2015 | 3 | 0.030 |
Why?
| | Computational Biology | 1 | 2020 | 649 | 0.030 |
Why?
| | Lactic Acid | 1 | 1997 | 303 | 0.030 |
Why?
| | Faculty, Medical | 1 | 2018 | 290 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 219 | 0.030 |
Why?
| | Cysticercosis | 1 | 1995 | 3 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 34 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1438 | 0.030 |
Why?
| | Cells, Cultured | 3 | 2006 | 4181 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 57 | 0.030 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 1995 | 32 | 0.030 |
Why?
| | Audiometry | 1 | 1995 | 27 | 0.030 |
Why?
| | Seat Belts | 1 | 1994 | 20 | 0.030 |
Why?
| | Nasal Cavity | 1 | 2015 | 57 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 1995 | 49 | 0.030 |
Why?
| | Aircraft | 1 | 1994 | 21 | 0.030 |
Why?
| | Cerebral Arteries | 1 | 2015 | 59 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4555 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 102 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 47 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 1995 | 113 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 45 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 1993 | 1352 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 1058 | 0.030 |
Why?
| | Personality Disorders | 1 | 2015 | 76 | 0.030 |
Why?
| | Neuroimaging | 1 | 2016 | 263 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1998 | 748 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 230 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 176 | 0.030 |
Why?
| | Computer Simulation | 1 | 1998 | 996 | 0.030 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2015 | 174 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 280 | 0.030 |
Why?
| | Cohort Studies | 2 | 2017 | 5697 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 220 | 0.030 |
Why?
| | Paresis | 2 | 2007 | 30 | 0.030 |
Why?
| | Nervous System | 1 | 1993 | 67 | 0.020 |
Why?
| | Hypothyroidism | 2 | 1992 | 73 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 285 | 0.020 |
Why?
| | Models, Biological | 1 | 2000 | 1806 | 0.020 |
Why?
| | Phosphopyruvate Hydratase | 1 | 1992 | 26 | 0.020 |
Why?
| | Safety | 1 | 1994 | 347 | 0.020 |
Why?
| | Mice | 4 | 2012 | 17814 | 0.020 |
Why?
| | Neuroblastoma | 1 | 1993 | 159 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 442 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1805 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 858 | 0.020 |
Why?
| | Antibodies, Monoclonal | 4 | 2008 | 1436 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 1993 | 255 | 0.020 |
Why?
| | Fatal Outcome | 2 | 2007 | 309 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1993 | 193 | 0.020 |
Why?
| | Vimentin | 1 | 1992 | 52 | 0.020 |
Why?
| | G2 Phase | 1 | 2012 | 39 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2049 | 0.020 |
Why?
| | Lymphocytosis | 1 | 1992 | 11 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3307 | 0.020 |
Why?
| | Rhodamine 123 | 2 | 2001 | 8 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 121 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 155 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2014 | 1317 | 0.020 |
Why?
| | Lymphocytes | 1 | 1993 | 395 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2011 | 20 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2015 | 450 | 0.020 |
Why?
| | Cytoplasm | 1 | 2012 | 270 | 0.020 |
Why?
| | Skull Base | 1 | 2011 | 51 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1991 | 38 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 665 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 398 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 163 | 0.020 |
Why?
| | Spleen | 1 | 1993 | 523 | 0.020 |
Why?
| | Intraoperative Care | 2 | 2003 | 62 | 0.020 |
Why?
| | Carcinoma | 1 | 2012 | 229 | 0.020 |
Why?
| | Algorithms | 1 | 1998 | 1740 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 73 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 146 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 129 | 0.020 |
Why?
| | Camptothecin | 1 | 2010 | 122 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1993 | 386 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2010 | 157 | 0.020 |
Why?
| | Vision Disorders | 2 | 2007 | 157 | 0.020 |
Why?
| | Doxorubicin | 2 | 2001 | 348 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 248 | 0.020 |
Why?
| | Salvage Therapy | 1 | 2010 | 151 | 0.020 |
Why?
| | Hypogonadism | 1 | 1990 | 92 | 0.020 |
Why?
| | Ultrasonography | 2 | 1984 | 745 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 19 | 0.020 |
Why?
| | Kinetics | 1 | 1992 | 1645 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 34 | 0.020 |
Why?
| | Follicle Stimulating Hormone | 3 | 1999 | 243 | 0.020 |
Why?
| | Axillary Artery | 1 | 1988 | 13 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 422 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 2044 | 0.020 |
Why?
| | Subclavian Artery | 1 | 1988 | 28 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 96 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 476 | 0.020 |
Why?
| | CD3 Complex | 1 | 2008 | 104 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 788 | 0.020 |
Why?
| | Infant, Newborn | 3 | 1997 | 6144 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 852 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 34 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3433 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 1992 | 454 | 0.020 |
Why?
| | Rituximab | 1 | 2008 | 202 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1233 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 508 | 0.020 |
Why?
| | Methotrexate | 1 | 2008 | 255 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1229 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 385 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1992 | 535 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 438 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1989 | 1092 | 0.020 |
Why?
| | Multigene Family | 1 | 2007 | 201 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 528 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 139 | 0.020 |
Why?
| | Tretinoin | 1 | 2006 | 122 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2008 | 304 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 428 | 0.010 |
Why?
| | Coma | 1 | 1985 | 35 | 0.010 |
Why?
| | Cognition | 1 | 2013 | 1179 | 0.010 |
Why?
| | Action Potentials | 1 | 1988 | 485 | 0.010 |
Why?
| | Athletic Injuries | 1 | 1991 | 517 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 364 | 0.010 |
Why?
| | Intracranial Pressure | 1 | 1985 | 60 | 0.010 |
Why?
| | Blood-Brain Barrier | 1 | 1985 | 141 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 1044 | 0.010 |
Why?
| | Brain Concussion | 1 | 1991 | 579 | 0.010 |
Why?
| | Citrates | 1 | 1984 | 41 | 0.010 |
Why?
| | Sound | 1 | 1984 | 48 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2339 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2008 | 785 | 0.010 |
Why?
| | Blood | 1 | 1984 | 113 | 0.010 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2003 | 49 | 0.010 |
Why?
| | Injections | 1 | 1984 | 189 | 0.010 |
Why?
| | Antigens, CD | 1 | 2006 | 536 | 0.010 |
Why?
| | Trauma Centers | 1 | 1985 | 428 | 0.010 |
Why?
| | Heparin | 1 | 1984 | 258 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 2001 | 71 | 0.010 |
Why?
| | Cyclosporins | 1 | 2001 | 71 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 150 | 0.010 |
Why?
| | Pulsatile Flow | 2 | 1991 | 55 | 0.010 |
Why?
| | Verapamil | 1 | 2001 | 40 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1488 | 0.010 |
Why?
| | Ultrasonic Therapy | 1 | 2001 | 15 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 1985 | 670 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 172 | 0.010 |
Why?
| | Luteinizing Hormone | 2 | 1991 | 183 | 0.010 |
Why?
| | Lung | 1 | 2013 | 4106 | 0.010 |
Why?
| | Fushi Tarazu Transcription Factors | 1 | 1999 | 5 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 991 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2155 | 0.010 |
Why?
| | Brown-Sequard Syndrome | 1 | 1998 | 5 | 0.010 |
Why?
| | Syringomyelia | 1 | 1998 | 11 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2923 | 0.010 |
Why?
| | Pyramidal Tracts | 1 | 1998 | 31 | 0.010 |
Why?
| | Sensation Disorders | 1 | 1998 | 37 | 0.010 |
Why?
| | Therapy, Computer-Assisted | 1 | 1998 | 62 | 0.010 |
Why?
| | Thoracic Vertebrae | 1 | 1998 | 77 | 0.010 |
Why?
| | Iatrogenic Disease | 1 | 1998 | 69 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 50 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 208 | 0.010 |
Why?
| | Photography | 1 | 1998 | 108 | 0.010 |
Why?
| | Spinal Fractures | 1 | 1998 | 74 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 72 | 0.010 |
Why?
| | Cervical Vertebrae | 1 | 1998 | 143 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 1998 | 165 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 148 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 336 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 233 | 0.010 |
Why?
| | Lumbar Vertebrae | 1 | 1998 | 249 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2006 | 5798 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1999 | 509 | 0.010 |
Why?
| | Praziquantel | 1 | 1995 | 5 | 0.010 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 1995 | 37 | 0.010 |
Why?
| | Spinal Cord Injuries | 1 | 1998 | 231 | 0.010 |
Why?
| | RNA, Viral | 1 | 1998 | 684 | 0.010 |
Why?
| | Carotid Stenosis | 1 | 1995 | 96 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 1941 | 0.010 |
Why?
| | Optic Chiasm | 1 | 1992 | 18 | 0.010 |
Why?
| | Nerve Compression Syndromes | 1 | 1992 | 22 | 0.010 |
Why?
| | Unconsciousness | 1 | 1991 | 21 | 0.010 |
Why?
| | Amnesia | 1 | 1991 | 46 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 167 | 0.010 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 1992 | 57 | 0.010 |
Why?
| | Headache | 1 | 1992 | 147 | 0.010 |
Why?
| | Football | 1 | 1991 | 87 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 5803 | 0.010 |
Why?
| | Immunochemistry | 1 | 1989 | 13 | 0.000 |
Why?
| | Autoradiography | 1 | 1989 | 69 | 0.000 |
Why?
| | Hyperthyroidism | 1 | 1989 | 23 | 0.000 |
Why?
| | Histocytochemistry | 1 | 1989 | 80 | 0.000 |
Why?
| | Circadian Rhythm | 1 | 1991 | 489 | 0.000 |
Why?
| | Neutrophils | 1 | 1989 | 1274 | 0.000 |
Why?
| | Transcription, Genetic | 1 | 1989 | 1470 | 0.000 |
Why?
| | Intraoperative Period | 1 | 1982 | 67 | 0.000 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 1982 | 29 | 0.000 |
Why?
| | Arteriovenous Malformations | 1 | 1982 | 29 | 0.000 |
Why?
| | Phenotype | 1 | 1989 | 3139 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1989 | 1986 | 0.000 |
Why?
| | Gene Expression Regulation | 1 | 1989 | 2590 | 0.000 |
Why?
| | Pregnancy | 1 | 1992 | 6829 | 0.000 |
Why?
|
|
Lillehei's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|